- The Queensland Parkinson’s Project: An Overview of 20 Years of Mortality from Parkinson’s Disease
-
Peter Cornelis Poortvliet, Alexander Gluch, Peter A. Silburn, George D. Mellick
-
J Mov Disord. 2021;14(1):34-41. Published online December 7, 2020
-
DOI: https://doi.org/10.14802/jmd.20034
-
-
11,499
View
-
231
Download
-
16
Web of Science
-
15
Crossref
-
 Abstract
 PDF
- Objective
The consensus is that life expectancy for individuals with Parkinson’s disease (PD) is reduced, but estimations vary. We aimed to provide an overview of 20 years of mortality and risk factor data from the Queensland Parkinson’s Project.
Methods
The analysis included 1,334 PD and 1,127 control participants. Preliminary analysis of baseline characteristics (sex, age at onset, family history, smoking status, pesticide exposure, depression and neurosurgery) was conducted, and Kaplan–Meier curves were generated for each potential risk factor. Standardized mortality ratios (SMRs) were calculated comparing this cohort to the general Australian population. Cox proportional hazards regression modeling was used to analyze potential predictors of mortality.
Results
In total, 625 (46.8%) PD and 237 (21.0%) control participants were deceased. Mean disease duration until death was 15.3 ± 7.84 years. Average ages at death were 78.0 ± 7.4 years and 80.4 ± 8.4 years for the deceased PD and control participants, respectively. Mortality was significantly increased for PD in general {SMR = 2.75 [95% confidence interval (CI): 2.53–2.96]; p = 0.001}. SMRs were slightly higher for women and those with an age of onset before 60 years. Multivariate analysis showed that deep brain stimulation (DBS) treatment was associated with lower mortality [hazard ratio (HR) = 0.76; 95% CI: 0.59–0.98], while occasional pesticide exposure increased mortality risk (HR = 1.48; 95% CI: 1.17–1.88). Family history of PD, smoking and depression were not independent predictors of mortality.
Conclusion
Mortality in PD is increased. Sex, age at onset and occasional pesticide exposure were independent determinants of increased mortality, while DBS treatment was associated with reduced mortality.
-
Citations
Citations to this article as recorded by  - Update: Descriptive epidemiology of Parkinson disease
Nikolas Grotewold, Roger L. Albin
Parkinsonism & Related Disorders.2024; 120: 106000. CrossRef - Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease
Nayoung Kwak, Myung-Jun Lee, Hye-Young Kang, Hankil Lee
Clinical Therapeutics.2024; 46(9): 670. CrossRef - Profiling people with Parkinson's disease at risk of cognitive decline: Insights from PPMI and ICICLE‐PD data
Dana Pourzinal, Rachael A. Lawson, Alison J. Yarnall, Caroline H. Williams‐Gray, Roger A. Barker, Jihyun Yang, Katie L. McMahon, John D. O'Sullivan, Gerard J. Byrne, Nadeeka N. Dissanayaka
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.2024;[Epub] CrossRef - Risk of aspiration pneumonia and hospital mortality in Parkinson disease: A systematic review and meta‐analysis
Wei Yu Chua, Jia Dong James Wang, Claire Kar Min Chan, Ling‐Ling Chan, Eng‐King Tan
European Journal of Neurology.2024;[Epub] CrossRef - Psychometric properties of Arabic-translated-related quality of life scales for people with parkinson disease: a scoping review
Chiraz Azaiez, Naser Chalghaf, Amayra Tannoubi, Noomen Guelmami, Medina Srem-Sai, Frank Quansah, John Elvis Hagan, Heifa Sneni, Ghada Boussayala, Imane Ghalmi, Mazin Inhaier Lami, Nicola Luigi Bragazzi, Stephane Mandigout, Choukri ben Ayed, Fairouz Azaiez
BMC Public Health.2024;[Epub] CrossRef - Indication for molecular testing by multiplex ligation‐dependent probe amplification in parkinsonism
E. Mutez, M. Swiderski, D. Devos, C. Moreau, G. Baille, A. Degardin, G. Ryckewaert, N. Carriere, A. Kreisler, C. Simonin, N. Rouaix, M. Tir, P. Krystkowiak, N. Ramdane, M. Génin, B. Sablonnière, L. Defebvre, V. Huin
European Journal of Neurology.2023; 30(6): 1667. CrossRef - Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
Amica C. Müller-Nedebock, Marieke C. J. Dekker, Matthew J. Farrer, Nobutaka Hattori, Shen-Yang Lim, George D. Mellick, Irena Rektorová, Mohamed Salama, Artur F. S. Schuh, A. Jon Stoessl, Carolyn M. Sue, Ai Huey Tan, Rene L. Vidal, Christine Klein, Soraya
npj Parkinson's Disease.2023;[Epub] CrossRef - Effects of omega-3 polyunsaturated fatty acids on the levels of pro- and anti-inflammatory cytokines and lipid profile in patients with Parkinson's disease
Sara Mohammadi, Mirmohsen Sharifi Bonab, Mahdyieh Hamed Behzad, Bahram Pourghassem Gargari
Nutrition Clinique et Métabolisme.2023; 37(3): 181. CrossRef - The elephant in the room: critical reflections on mortality rates among individuals with Parkinson’s disease
Lisanne J. Dommershuijsen, Sirwan K. L. Darweesh, Yoav Ben-Shlomo, Benzi M. Kluger, Bastiaan R. Bloem
npj Parkinson's Disease.2023;[Epub] CrossRef - Mortality of Parkinson’s disease in Italy from 1980 to 2015
Monica Ulivelli, Daiana Bezzini, Lucia Kundisova, Ilaria Grazi, Mario Alberto Battaglia, Nicola Nante, Simone Rossi
Neurological Sciences.2022; 43(6): 3603. CrossRef - A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population
Brage Brakedal, Lilah Toker, Kristoffer Haugarvoll, Charalampos Tzoulis
npj Parkinson's Disease.2022;[Epub] CrossRef - Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
Svetlana Bivol, George D Mellick, Jacob Gratten, Richard Parker, Aoibhe Mulcahy, Philip E Mosley, Peter C Poortvliet, Adrian I Campos, Brittany L Mitchell, Luis M Garcia-Marin, Simone Cross, Mary Ferguson, Penelope A Lind, Danuta Z Loesch, Peter M Vissche
BMJ Open.2022; 12(2): e052032. CrossRef - Therapeutic targeting of mitophagy in Parkinson's disease
Shashank Masaldan, Sylvie Callegari, Grant Dewson
Biochemical Society Transactions.2022; 50(2): 783. CrossRef - Worldwide trends in mortality related to Parkinson's disease in the period of 1994–2019: Analysis of vital registration data from the WHO Mortality Database
Ioannis C. Lampropoulos, Foteini Malli, Olga Sinani, Konstantinos I. Gourgoulianis, Georgia Xiromerisiou
Frontiers in Neurology.2022;[Epub] CrossRef - Effects of physician visit frequency for Parkinson’s disease treatment on mortality, hospitalization, and costs: a retrospective cohort study
Takako Fujita, Akira Babazono, Sung-a Kim, Aziz Jamal, Yunfei Li
BMC Geriatrics.2021;[Epub] CrossRef
|
KMDS
E-submission
